IPOD-3: Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery

Sponsor
Nestlé (Industry)
Overall Status
Terminated
CT.gov ID
NCT01023412
Collaborator
(none)
107
6
2
28
17.8
0.6

Study Details

Study Description

Brief Summary

Major surgery is still associated with a high rate of postoperative morbidity despite improved techniques in surgical management. Surgery-induced alterations of the immune system are well described and may play a role in the genesis of postoperative complications. It has been shown by several large scale clinical trials, that the use of immunonutrition in postoperative cancer surgery, trauma and critically ill patients resulted in an improved immunocompetence and/or reduced postoperatively infectious morbidity and/or length of hospital stay.The pre-operative regimen was between 5 to 7 days of treatment. The aim of this trial is to evaluate if a shorter administration of 3 days pre-operatively would be beneficial as well.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Immunonutrition
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
107 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial
Study Start Date :
Jan 1, 2006
Actual Primary Completion Date :
May 1, 2008
Actual Study Completion Date :
May 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Nutritional product

Oral nutritional supplement containing immuno nutrients

Dietary Supplement: Immunonutrition
Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).

Placebo Comparator: Isocaloric control

Isocaloric and isonitrogenous control without immuno nutrients

Dietary Supplement: Immunonutrition
Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).

Outcome Measures

Primary Outcome Measures

  1. Rate of post-operative complications [On the day of discharge from hospital]

Secondary Outcome Measures

  1. Incidence of non-infectious complications [On the day of discharge from hospital]

  2. Length of hospital stay [On the day of discharge from hospital]

  3. Nutritional status evaluation [On the day of discharge from hospital]

  4. Rate of post-operative infectious complications [On the day of discharge from hospital]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with GI cancer (stomach, pancreas, small and large bowel and rectum) histologically proven

  • Well nourished patients as defined by a total score of <3 on the nutritional screening tool NRS-2002 (46) (Appendix III)

  • Patients who are >= 18 years of age;

  • Patients who have signed a written Informed Consent (Appendix I) prior to admission to the study;

  • Patients who have an ECOG performance status of 0, 1 or 2 (Appendix II).

  • Patients able to orally consume 750 mL or more of liquid a day prior to surgery

Exclusion Criteria:
  • Patients who have co-morbid conditions, uncontrolled metabolic conditions or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult;

  • Patients who are pregnant;

  • Patients with cardiac failure as defined by the Goldman classification class>3

  • Patients with respiratory failure (FEV<0.8l/sec)

  • Patients with renal failure (Cr >= 3mg/dl or dialysis patients)

  • Patients with hepatic dysfunction (Child >A)

  • Patients suffering from an intestinal obstruction or ileum

  • Patients with an Hb level of <=8 g/dL experiencing gastrointestinal hemorrhaging

  • Patients with HIV, HCV, HBV

  • Patients requiring immunosuppression treatments

  • Patients undergoing emergency surgery

  • Other patients determined by a study investigator to be inappropriate for enrolment in this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kantonsspital Aarau Aarau Switzerland 5001
2 Kantonsspital Baden Baden Switzerland 5404
3 Lindenhof-Spital Bern Switzerland 3012
4 Kantonsspital Liestal Liestal Switzerland 4410
5 Kantonsspital Schaffausen Schaffhausen Switzerland 8208
6 Kantonsspital St.Gallen St.Gallen Switzerland 9000

Sponsors and Collaborators

  • Nestlé

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nestlé
ClinicalTrials.gov Identifier:
NCT01023412
Other Study ID Numbers:
  • SC-IRTD-01-05-CH
First Posted:
Dec 2, 2009
Last Update Posted:
Apr 25, 2012
Last Verified:
Apr 1, 2012
Keywords provided by Nestlé
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 25, 2012